Nautilus Biotechnology reported narrower Q1 losses and began rolling out early access for its Voyager protein analysis platform. The Seattle-based company said it reduced its net loss to $14.7 million in the first quarter from $16.6 million a year earlier, helped by declines in R&D and operating expense. Nautilus attributed the commercialization push to early customer engagement, which it said reinforced demand for real-world protein analysis workflows. The company also advanced a next-generation assay format aimed at improving probe compatibility, performance, and scalability. During the quarter, researchers at Baylor University began using Voyager to benchmark a bioinformatics tool for characterizing protein isoforms from shotgun mass spectrometry data—one of the first listed early access customers. With $14.6 million in cash and $81.2 million in short-term investments at quarter end, Nautilus is positioning Voyager for broader commercial availability after initial validation in external labs.